Most recent by Paul Schulman, MD
Peresolimab superior to placebo for rheumatoid arthritis treatment
Peresolimab 700 mg is superior to placebo in the treatment of moderate-to-severe rheumatoid arthritis, according to data published in the New England Journal of Medicine.
Litifilimab superior to placebo in reducing tender, swollen joints in lupus
Litifilimab is superior to placebo in reducing tender and swollen joints among patients with systemic lupus erythematosus, according to phase 2 trial data published in the New England Journal of Medicine.
Patients with gut dysbiosis show worse axial SpA disease activity, physical function
Gut dysbiosis is more frequent in patients with ankylosing spondylitis, compared with controls, and is associated with worse axial spondyloarthritis disease activity and physical function, according to data.
More than 200,000 people in US meet criteria for systemic lupus erythematosus
More than 200,000 people in the United States met the American College of Rheumatology criteria for systemic lupus erythematosus in 2018, according to data published in Arthritis & Rheumatology.